NeOnc Technologies schedules FDA end-of-Phase 1 meeting for NEO212

• NeOnc Technologies will hold an in-person FDA End-of-Phase 1 Type B meeting on Nov. 17, 2026, for NEO212.
• Discussion will cover Phase 2 study design, dose selection, endpoints, and evidence needed to support a future marketing application.
• NeOnc will also seek FDA feedback on whether its proposed development plan could support an accelerated approval pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-010493), on September 28, 2026, and is solely responsible for the information contained therein.